Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05770037
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:55.877345+00:00
Published At
2025-11-24T00:00:00+00:00
Record Updated At
2025-11-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Haematological Malignancy", "Malignant Neoplasm", "Lymphoproliferative Disorders", "Neoplasms by Histologic Type", "Neoplasms by Site", "Cancer", "Anaplastic Large Cell Lymphoma", "Lymphoma", "Renal Cell Carcinoma", "Neuroblastoma", "Solid Tumour"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-11-24"
protocolSection.identificationModule.nctId
"NCT05770037"
protocolSection.identificationModule.officialTitle
"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Haematological Malignancy (protocolSection.conditionsModule.conditions)
  • Malignant Neoplasm (protocolSection.conditionsModule.conditions)
  • Lymphoproliferative Disorders (protocolSection.conditionsModule.conditions)
  • Neoplasms by Histologic Type (protocolSection.conditionsModule.conditions)
  • Neoplasms by Site (protocolSection.conditionsModule.conditions)
  • Cancer (protocolSection.conditionsModule.conditions)
  • Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphoma (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Solid Tumour (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.